Stock RARE ULTRAGENYX PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Real-time Estimate Cboe BZX
Other stock markets
 01:21:02 2024-04-16 pm EDT 		5-day change 1st Jan Change
43.87 USD +2.33% Intraday chart for Ultragenyx Pharmaceutical Inc. -13.53% -8.57%
Apr. 15 Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Apr. 15 Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement' MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup
DJ
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting
AQ
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
AQ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'
MT
Sector Update: Health Care Stocks Advance Premarket Monday
MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
GL
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
CI
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
GL
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating
MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing
MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM
Ultragenyx to Participate at Investor Conferences in March
GL
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RARE Stock
  4. News Ultragenyx Pharmaceutical Inc.